Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Paraguay has been on the rise in recent years.
Customer preferences: Patients in Paraguay have shown a preference for non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of rheumatoid arthritis. However, due to the side effects associated with long-term use of NSAIDs, there has been a shift towards disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents.
Trends in the market: The Anti-Rheumatic Drugs market in Paraguay has been growing steadily due to the increasing prevalence of rheumatoid arthritis in the country. The availability of new and innovative drugs has also contributed to the growth of the market. The market is expected to continue to grow in the coming years due to the aging population and the increasing awareness about rheumatoid arthritis.
Local special circumstances: The healthcare system in Paraguay is fragmented, with a large portion of the population lacking access to quality healthcare services. This has led to a significant number of undiagnosed cases of rheumatoid arthritis. However, the government has taken steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to drive the demand for Anti-Rheumatic Drugs in the coming years.
Underlying macroeconomic factors: Paraguay has experienced steady economic growth in recent years, which has led to an increase in disposable income and improved access to healthcare services. The government has also implemented policies to attract foreign investment, which has led to an increase in the availability of new and innovative drugs in the market. The favorable economic conditions are expected to continue to drive the growth of the Anti-Rheumatic Drugs market in Paraguay.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
